Topic: Catherine Arnold
NEW YORK/LONDON (Reuters) - Bristol-Myers Squibb Co's shares rose more than 8 percent on Monday after news over the weekend that its experimental drug ipilimumab extended survival in patients with deadly skin cancer.Bristol's ipilimumab added an average
Drugmakers Merck & Co. and partner Schering-Plough Corp. both posted fourth-quarter results Tuesday that topped analysts' expectations, sending their shares up, but revenues from their crucial cholesterol franchise plunged.Both companies beat